IRD (Opus Genetics) Business Value to Revenue

Opus Genetics, Inc. (IRD) - corporate logo

Opus Genetics Inc (IRD) is implementing ESG environmental standards into the development of gene therapies while strictly adhering to bioethics. This EV/Sales chart demonstrates the model's resilience, where the value of 43142.86 expresses the metric level. Process optimization relies on the outsourcing of logistics and testing. The development of unique orphan drugs for the retina provides the company with a market monopoly due to the absence of analogues.

EV/Sales Multiple: Opus Bio (IRD) for 11/23/2025 - 11/20/2026

Opus Bio - analytical breakdowns and key metrics (IRD)

- market price and analyst price targets:
- business market valuation indicators:
Fundamental valuation:Opus Genetics, Inc. (IRD)
Finished products of Opus Genetics, Inc.

This indicator determines the market value of the entire business, accounting for net debt per unit of revenue, allowing for an assessment of asset monetization efficiency regardless of financial leverage. By analyzing the enterprise value-to-annual revenue multiple, an investor can confirm the premium valuation of Opus Genetics Inc. (IRD), justified by exclusive patents for delivery vectors and high barriers to entry in the gene therapy segment.